One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion.
Nancy WangAdrian HuntVuong NguyenJanika ShahSamantha Fraser-BellIan McAllisterDaniel BarthelmesMark GilliesDavid SquirrellPublished in: Clinical & experimental ophthalmology (2022)
Bevacizumab can be an effective treatment of RVO-MO in a real-world setting with outcomes approaching those reported by the seminal clinical trials. The functional and anatomical outcomes of intravitreal therapy were better for BRVO than CRVO.
Keyphrases
- clinical trial
- diabetic retinopathy
- optical coherence tomography
- type diabetes
- randomized controlled trial
- metabolic syndrome
- metastatic colorectal cancer
- vascular endothelial growth factor
- adipose tissue
- mesenchymal stem cells
- skeletal muscle
- replacement therapy
- weight loss
- open label
- cell therapy
- study protocol
- smoking cessation
- optic nerve
- phase iii